PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kramvis, A.* ; Chang, K.M.* ; Dandri, M.* ; Farci, P.* ; Glebe, D.* ; Hu, J.* ; Janssen, H.L.A.* ; Lau, D.T.Y.* ; Penicaud, C.* ; Pollicino, T.* ; Testoni, B.* ; Van Bömmel, F.* ; Andrisani, O.* ; Beumont-Mauviel, M.* ; Block, T.M.* ; Chan, H.L.Y.* ; Cloherty, G.A.* ; Delaney, W.E.* ; Geretti, A.M.* ; Gehring, A.* ; Jackson, K.* ; Lenz, O.* ; Maini, M.K.* ; Miller, V.* ; Protzer, U. ; Yang, J.C.* ; Yuen, M.F.* ; Zoulim, F.* ; Revill, P.A.*

A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook.

Nat. Rev. Gastroenterol. Hepatol. 19, 727-745 (2022)
Postprint Forschungsdaten DOI PMC
Open Access Green
Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
73.082
0.000
12
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1759-5045
e-ISSN 1759-5053
Zeitschrift Nature Reviews - Gastroenterology & Hepatology
Quellenangaben Band: 19, Heft: 11, Seiten: 727-745 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
DOI 10.1038/s41575-022-00649-z
WOS ID WOS:000828259600001
Scopus ID 85134550873
PubMed ID 35859026
Erfassungsdatum 2022-07-27
[➜Korrektur melden]